uMotif

uMotif Announces Andrea Valente is Chief Executive Officer

BOSTON and LONDON, June 1, 2026 -- uMotif – one of the fastest-growing companies in the clinical trial technology market – announces Andrea Valente is now Chief Executive Officer, effective today. Valente takes over from former CEO Steve Rosenberg, who has retired but will remain on uMotif's Board of Directors. Valente brings over 20 years of achievement across the life...

uMotif Harnesses AI to Deliver Faster, Higher-Quality Clinical Trials with MotifAI Assistant

Boston, US, and London, UK – November 3, 2025 –  uMotif – one of the clinical technology market’s fastest-growing companies – today announced a multi-phase deployment of MotifAI Assistant, its AI-driven automation, across its product portfolio. uMotif’s portfolio is anchored by modern, patient-first eCOA/ePRO, and enhanced by solutions for consent management, trial awareness, patient transport, and site productivity....

Life Science and Healthcare Industry Executive Adam Deutsch Joins uMotif Board as Company Brings the Next-Generation of eCOA/ePRO to Expanding Global Market

BOSTON, Mass. - March 15, 2023 óuMotif - one of the clinical trial technology marketís fastest growing companies - bolstered its status as the leader in next-generation eCOA/ePRO with the announcement that life science and healthcare executive Adam Deutsch has joined its Board of Directors.

uMotif Announces First New Validated Innovation in eCOA/ePRO Since Paper Instruments Were Deployed on Smartphones

Patent-protected Motif data capture interface proven as equivalent method to capture Patient Reported Outcome and eDiary data, eliminates reliance on text-based instruments, in study with 55 participants in 2 randomized groups conducted by SAFIRA Clinical Research at Dublin City University

uMotif ‚Ä’ the patient-first data capture and decentralized clinical trials platform ‚Ä’ announces $25.5m of new investment from a fund managed by Athyrium Capital Management

LONDON and NEW YORK, May 25, 2022-- uMotif today announced a new investment of $25.5m from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif's unique patient-first software platform for clinical research.
2th Floor, WeWork, 10 York Road, London, SE1 7ND, United Kingdom